Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin

Oncol Rep. 2001 Jul-Aug;8(4):807-10. doi: 10.3892/or.8.4.807.

Abstract

Human colon cancer SW480DDP and SW620DDP cells resistant to cisplatin exhibited stronger c-myb gene expression than the parent SW480 and SW620 cells. However, cell growth rates in the cisplatin-resistant cell lines remained similar to those of the parent cells. Antisense oligonucleotides to c-myb inhibited c-myb expression and induced increased sensitivity to cisplatin in SW480DDP and SW620DDP cells, but this did not occur with the control sense oligonucleotides. In contrast, the parent cell lines were not affected by antisense oligonucleotides to c-myb. These results indicate that the c-myb gene in human colon cancer is one of the factors related to cisplatin resistance, and support the need to develop anti-cancer therapeutics based on oncogene-targeted antisense oligonucleotide technology.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Antineoplastic Agents / therapeutic use*
  • Cell Division / drug effects
  • Cisplatin / therapeutic use*
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / genetics
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Genes, myb
  • Humans
  • Oligonucleotides, Antisense / therapeutic use*
  • Polymerase Chain Reaction
  • Proto-Oncogene Proteins c-myb / biosynthesis
  • Proto-Oncogene Proteins c-myb / genetics*
  • RNA, Messenger / analysis
  • RNA, Messenger / genetics
  • RNA, Neoplasm / analysis
  • RNA, Neoplasm / genetics
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Oligonucleotides, Antisense
  • Proto-Oncogene Proteins c-myb
  • RNA, Messenger
  • RNA, Neoplasm
  • Cisplatin